Shattuck Labs (NASDAQ:STTK) Upgraded by Wall Street Zen to Hold Rating

Key Points

• Wall Street Zen has upgraded Shattuck Labs (NASDAQ:STTK) to a "hold" rating following analysts' reports on the stock.
• Shattuck Labs' recent performance shows a market capitalization of $74.25 million and a one-year stock range of $0.69 to $3.95.
• Insider buying activity includes Director Mona Ashiya purchasing over 6 million shares at an average price of $0.87, significantly increasing her ownership stake.

Shattuck Labs (NASDAQ:STTK - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a report released on Friday.

Several other research firms have also weighed in on STTK. Leerink Partners reduced their price objective on shares of Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating for the company in a research report on Thursday, August 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of Shattuck Labs in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Shattuck Labs presently has a consensus rating of "Moderate Buy" and a consensus target price of $4.00.

Shattuck Labs Stock Performance

Shares of STTK stock traded up $0.13 on Friday, hitting $2.01. The stock had a trading volume of 1,433,061 shares, compared to its average volume of 945,325. The firm has a market capitalization of $96.28 million, a price-to-earnings ratio of -1.66 and a beta of 1.64. The stock's 50 day moving average is $0.91 and its 200-day moving average is $1.00. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $3.95.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. Equities analysts expect that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Buying and Selling at Shattuck Labs

In related news, Director Orbimed Advisors Llc purchased 6,306,127 shares of Shattuck Labs stock in a transaction that occurred on Monday, August 25th. The shares were acquired at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. This represents a -600.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Mona Ashiya purchased 6,306,127 shares of Shattuck Labs stock in a transaction that occurred on Monday, August 25th. The shares were bought at an average price of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares in the company, valued at $4,571,942.22. This represents a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by insiders.

Institutional Trading of Shattuck Labs

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in shares of Shattuck Labs by 265.4% in the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company's stock valued at $41,000 after acquiring an additional 31,355 shares during the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Shattuck Labs in the 2nd quarter valued at about $44,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Shattuck Labs in the 4th quarter valued at about $45,000. Nuveen LLC bought a new stake in shares of Shattuck Labs in the 1st quarter valued at about $50,000. Finally, Bridgeway Capital Management LLC increased its stake in shares of Shattuck Labs by 147.5% in the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company's stock valued at $73,000 after acquiring an additional 55,000 shares during the last quarter. 58.74% of the stock is owned by institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.